Online inquiry

IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4104MR)

This product GTTS-WQ4104MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets oxLDL gene. The antibody can be applied in Atherosclerosis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000041.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 348
UniProt ID P02649
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4104MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11491MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MetMAb
GTTS-WQ9394MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ586MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 62-71-3
GTTS-WQ12054MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ11075MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ8453MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HspE7
GTTS-WQ10999MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ538MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 4D11
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW